Day: September 3, 2025

FLORHAM PARK, N.J., Sept. 03, 2025 (GLOBE NEWSWIRE) — Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced the acceptance of an abstract for poster presentation at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer Research taking place September 28-October 1 in Boston, Massachusetts. The poster presentation will highlight preclinical data from CLR 121225, the Company’s novel actinium-based radio conjugate alpha-emitter for treatment in hypoxic pancreatic ductal adenocarcinoma. “We are excited to present our poster at the AACR Special Conference on Pancreatic Cancer, further showcasing the potential of CLR 121225 for solid tumors,” said Jarrod Longcor, chief...

KISSIMMEE, Fla., Sept. 03, 2025 (GLOBE NEWSWIRE) — ECD Automotive Design proudly introduces Project Oliver, a 1996 Land Rover Defender D110 Signature Edition that redefines modern adventure. Purpose-built from the ground up, this hand-crafted Defender merges raw capability with elevated luxury, offering a seamless blend of rugged performance and refined design. Every detail, from its powerhouse V8 engine to its meticulously tailored interior, speaks to ECD’s philosophy of creating vehicles that reflect each client individually. Images for Oliver Video for Oliver At its core, Project Oliver is powered by a robust LT1 V8 engine, paired with a 10-speed automatic transmission, delivering commanding performance both on and off the road. Ready for sand and snow, this build has a central locking differential, heavy-duty axles, BREMBO...

WILMINGTON, Del., Sept. 03, 2025 (GLOBE NEWSWIRE) — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx Pharmaceuticals”, or the “Company”), a clinical-stage biopharmaceutical company, and HOPE Therapeutics, Inc., (“HOPE,” or the “Company”), an interventional psychiatry network wholly owned by NRx Pharmaceuticals, today announced that Jonathan Javitt, M.D., M.P.H., Chairman and Chief Executive Officer of NRx Pharmaceuticals, will participate in a fireside chat at H.C. Wainwright’s 27th Annual Global Investment Conference on Monday, September 8, 2025, from 4:30 to 5:00 PM ET. A webcast of the fireside chat will be available on the Events page of the Investors section of the Company’s website at https://ir.nrxpharma.com/events. A replay of the webcast will be available two hours after the...

WASHINGTON, Sept. 03, 2025 (GLOBE NEWSWIRE) — 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees Pharma” or the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne diseases, announced today the webcast link and change of date for management’s live presentation at the H.C. Wainwright 27th Annual Global Investment Conference in New York City, to Tuesday, September 9, 3:30 PM Eastern Time. Dr. Geoff Dow, 60 Degrees Pharma CEO, will present live and management will conduct one-on-one meetings during the conference. Event: H.C. Wainwright 27th Annual Global Investment ConferenceDate: September 9, 2025Time: 3:30 PM ETLocation: Lotte New York Palace HotelWebcast: Register About 60 Degrees Pharmaceuticals, Inc.60 Degrees Pharmaceuticals, Inc., founded in 2010, specializes in developing...

September 16 event to highlight preclinical data on the combination of FTI agents with multiple classes of targeted therapies October 18 event to review clinical data from the ESMO Congress 2025, including first clinical data from KO-2806 SAN DIEGO, Sept. 03, 2025 (GLOBE NEWSWIRE) — Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for cancer, today announced it will host two virtual investor and analyst events to spotlight its innovative farnesyl transferase inhibitor (FTI) program. These events will underscore Kura’s leadership in targeting cancer signaling pathways to address unmet needs in solid tumors and hematologic malignancies. Event Details:FTI Preclinical Program Review: Synergistic Combinations with Targeted TherapiesTuesday, September...

TORONTO, Sept. 03, 2025 (GLOBE NEWSWIRE) — Base Carbon Inc. (Cboe CA: BCBN) (OTCQX: BCBNF) with operations through its wholly-owned subsidiary, Base Carbon Capital Partners Corp. (“BCCPC”, together, with affiliates, “Base Carbon”, or the “Company”), is pleased to announce it has acquired additional expansion options for its India Afforestation, Reforestation and Revegetation Project. Additionally, the Company is pleased to announce it will host an investor town hall on Tuesday, September 30, 2025, at 11:00 a.m. Eastern Time. Options to Expand the India Afforestation, Reforestation, and Revegetation (ARR) Project The Company, through BCCPC, has been granted two contractual options to expand the India ARR Project at no additional cost to the Company. In securing the additional options, the Company modified its previously committed...

PURCHASE, N.Y., Sept. 03, 2025 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, announced that the Phase 2 ‘START’ Study has reached the 75% enrollment mark. The START Study is enrolling approximately 540 individuals with mild cognitive impairment (MCI) and early Alzheimer’s disease who will be treated with zervimesine (CT1812) or placebo for 18 months. Cognition is conducting the study in collaboration with the Alzheimer’s Clinical Trials Consortium (ACTC) with funding from the National Institute of Aging (NIA) at the National Institutes of Health. “We believe the strong enrollment pace in the START Study is due to interest on the part of patients and investigators in the potential of a convenient, once-daily...

PALO ALTO, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced the Company will host an investor webinar on Wednesday, September 10, 2025 at 8:00 am ET with Rachel Gafni, M.D., Senior Research Physician at the National Institute of Dental and Craniofacial Research, part of the National Institutes of Health (NIH) and Principal Investigator and Steering Committee Co-Chair for CALIBRATE, the Company’s Phase 3 clinical trial for autosomal dominant hypocalcemia type 1 (ADH1). Dr. Gafni will provide an overview of ADH1, specifically focusing on pathophysiology, the current unmet need, and the rationale for evaluating encaleret as a treatment for ADH1. In addition to Dr. Gafni, executive members...

Multi-year BSS platform support renewal strengthens Digitel’s ability to scale, innovate and deliver 5G-powered customer experiences TORONTO, Sept. 03, 2025 (GLOBE NEWSWIRE) — Digitel, a leading mobile network operator in Venezuela, has extended its partnership with Optiva, signing a multi-year services renewal agreement, reinforcing its commitment to innovation and rapid growth. The renewal empowers Digitel to further leverage Optiva’s full-stack BSS platform, including charging, billing and provisioning, enabling Digitel to accelerate time to market and expand its product portfolio with the confidence of continued platform reliability and stability. Digitel serves more than 7.2 million subscribers and recently became the first operator to offer 5G technology to the Venezuelan market. Since 2014, its collaboration with Optiva...